Anebulo Pharmaceuticals Ownership 2024 | Who Owns Anebulo Pharmaceuticals Now?


OverviewForecastFinancialsChart

Institutional Ownership

3.29%

Insider Ownership

65.38%

Retail Ownership

31.33%

Institutional Holders

8.00

Anebulo Pharmaceuticals Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
22NW, LP20.81%13.27%5,366,290--15,401,252Mar 31, 2024
LVW ADVISORS, LLC2.49%0.31%642,039-1,000-0.16%1,842,652Mar 31, 2024
NANTAHALA CAPITAL MANAGEMENT, LLC1.98%0.08%511,073--1,466,780Mar 31, 2024
MORGAN STANLEY1.55%0.00%399,219--1,145,759Mar 31, 2024
IKARIAN CAPITAL, LLC0.61%0.05%157,862--453,064Mar 31, 2024
VANGUARD GROUP INC0.60%-153,4724690.31%440,465Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.10%-25,25325,253100.00%72,476Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.09%-22,77722,777100.00%65,430Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC0.07%0.00%18,978--54,467Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.02%0.00%5,138-3,964-43.55%14,746Mar 31, 2024
BLACKROCK INC.0.02%-4,049-96-2.32%11,620Mar 31, 2024
UBS GROUP AG0.00%-144144100.00%413Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-6211.64%178,000Mar 31, 2024
JPMORGAN CHASE & CO--99100.00%26Mar 31, 2024
BANK OF AMERICA CORP /DE/----4-100.00%-Mar 31, 2024
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.----15,000-100.00%-Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC----1,217-100.00%-Mar 31, 2024

Anebulo Pharmaceuticals's largest institutional shareholder is 22NW, LP, holding 20.81% of the company's total share outstanding, currently valued at $15.40M. The top 10 institutional shareholders own together 28.31% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
22NW, LP20.81%13.27%5,366,290--15,401,252Mar 31, 2024
LVW ADVISORS, LLC2.49%0.31%642,039-1,000-0.16%1,842,652Mar 31, 2024
NANTAHALA CAPITAL MANAGEMENT, LLC1.98%0.08%511,073--1,466,780Mar 31, 2024
IKARIAN CAPITAL, LLC0.61%0.05%157,862--453,064Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC0.07%0.00%18,978--54,467Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.02%0.00%5,138-3,964-43.55%14,746Mar 31, 2024
MORGAN STANLEY1.55%0.00%399,219--1,145,759Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.10%-25,25325,253100.00%72,476Mar 31, 2024
VANGUARD GROUP INC0.60%-153,4724690.31%440,465Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.09%-22,77722,777100.00%65,430Mar 31, 2024
BLACKROCK INC.0.02%-4,049-96-2.32%11,620Mar 31, 2024
UBS GROUP AG0.00%-144144100.00%413Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-6211.64%178,000Mar 31, 2024
JPMORGAN CHASE & CO--99100.00%26Mar 31, 2024
BANK OF AMERICA CORP /DE/----4-100.00%-Mar 31, 2024
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.----15,000-100.00%-Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC----1,217-100.00%-Mar 31, 2024

The largest Anebulo Pharmaceuticals shareholder by % of total assets is 22NW, LP. The company owns 5.37M shares of Anebulo Pharmaceuticals (ANEB), representing 13.27% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.10%-25,25325,253100.00%72,476Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.09%-22,77722,777100.00%65,430Mar 31, 2024
VANGUARD GROUP INC0.60%-153,4724690.31%440,465Mar 31, 2024
UBS GROUP AG0.00%-144144100.00%413Mar 31, 2024
JPMORGAN CHASE & CO--99100.00%26Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-6211.64%178,000Mar 31, 2024
MORGAN STANLEY1.55%0.00%399,219--1,145,759Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC0.07%0.00%18,978--54,467Mar 31, 2024
IKARIAN CAPITAL, LLC0.61%0.05%157,862--453,064Mar 31, 2024
NANTAHALA CAPITAL MANAGEMENT, LLC1.98%0.08%511,073--1,466,780Mar 31, 2024
22NW, LP20.81%13.27%5,366,290--15,401,252Mar 31, 2024
BANK OF AMERICA CORP /DE/----4-100.00%-Mar 31, 2024
BLACKROCK INC.0.02%-4,049-96-2.32%11,620Mar 31, 2024
LVW ADVISORS, LLC2.49%0.31%642,039-1,000-0.16%1,842,652Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC----1,217-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.02%0.00%5,138-3,964-43.55%14,746Mar 31, 2024
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.----15,000-100.00%-Mar 31, 2024

As of Mar 31 2024, Anebulo Pharmaceuticals's largest institutional buyer is SUSQUEHANNA INTERNATIONAL GROUP, LLP. The company purchased 25.25K stocks of ANEB, valued at $72.48K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.----15,000-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.02%0.00%5,138-3,964-43.55%14,746Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC----1,217-100.00%-Mar 31, 2024
LVW ADVISORS, LLC2.49%0.31%642,039-1,000-0.16%1,842,652Mar 31, 2024
BLACKROCK INC.0.02%-4,049-96-2.32%11,620Mar 31, 2024
BANK OF AMERICA CORP /DE/----4-100.00%-Mar 31, 2024
22NW, LP20.81%13.27%5,366,290--15,401,252Mar 31, 2024
NANTAHALA CAPITAL MANAGEMENT, LLC1.98%0.08%511,073--1,466,780Mar 31, 2024
IKARIAN CAPITAL, LLC0.61%0.05%157,862--453,064Mar 31, 2024
BOOTHBAY FUND MANAGEMENT, LLC0.07%0.00%18,978--54,467Mar 31, 2024
MORGAN STANLEY1.55%0.00%399,219--1,145,759Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-6211.64%178,000Mar 31, 2024
JPMORGAN CHASE & CO--99100.00%26Mar 31, 2024
UBS GROUP AG0.00%-144144100.00%413Mar 31, 2024
VANGUARD GROUP INC0.60%-153,4724690.31%440,465Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.09%-22,77722,777100.00%65,430Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.10%-25,25325,253100.00%72,476Mar 31, 2024

As of Mar 31 2024, Anebulo Pharmaceuticals's biggest institutional seller is LANDSCAPE CAPITAL MANAGEMENT, L.L.C.. The company sold -15.00K shares of ANEB, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.10%-25,25325,253100.00%72,476Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.09%-22,77722,777100.00%65,430Mar 31, 2024
UBS GROUP AG0.00%-144144100.00%413Mar 31, 2024
JPMORGAN CHASE & CO--99100.00%26Mar 31, 2024

Anebulo Pharmaceuticals's largest new institutional shareholder by number of shares is SUSQUEHANNA INTERNATIONAL GROUP, LLP, purchased 25.25K shares, valued at $72.48K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.----15,000-100.00%-Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC----1,217-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----4-100.00%-Mar 31, 2024

Anebulo Pharmaceuticals's largest sold out institutional shareholder by shares sold is LANDSCAPE CAPITAL MANAGEMENT, L.L.C., sold -15.00K shares, valued at -, as of undefined.

Anebulo Pharmaceuticals Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD INDEX FUNDS0.00%65,82944,829213.47%Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%7,4071,42023.72%Feb 29, 2024
EQ ADVISORS TRUST0.00%366--Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%636--Dec 31, 2023
iSHARES TRUST0.00%3,779--Feb 29, 2024

Anebulo Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 65.83K shares, compromising 0.00% of its total assets.

Anebulo Pharmaceuticals Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 248-38.46%
31 Dec, 231318.18%
30 Sep, 2311-
30 Jun, 231122.22%
31 Mar, 239-25.00%
31 Dec, 221220.00%
30 Sep, 221025.00%
30 Jun, 228-
31 Mar, 228-
31 Dec, 21814.29%
30 Sep, 217-12.50%
30 Jun, 218-

As of 31 Mar 24, 8 institutions are holding Anebulo Pharmaceuticals's shares, representing a decrease of -38.46% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 24847,805-88.35%
31 Dec, 237,278,9933.24%
30 Sep, 237,050,4910.26%
30 Jun, 237,031,8832.86%
31 Mar, 236,836,130-2.98%
31 Dec, 227,046,3072.97%
30 Sep, 226,842,91246.28%
30 Jun, 224,677,84711.63%
31 Mar, 224,190,412-0.07%
31 Dec, 214,193,3070.24%
30 Sep, 214,183,214-0.40%
30 Jun, 214,199,876-

Anebulo Pharmaceuticals (ANEB) has 847.80K shares outstanding as of 31 Mar 24, down -88.35% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 243.29%0.41%
31 Dec, 2328.22%3.57%
30 Sep, 2328.12%3.74%
30 Jun, 2327.43%3.86%
31 Mar, 2326.67%3.53%
31 Dec, 2227.49%3.22%
30 Sep, 2229.22%7.28%
30 Jun, 2220.04%6.22%
31 Mar, 2217.95%5.56%
31 Dec, 2117.96%5.59%
30 Sep, 2117.92%3.40%
30 Jun, 2122.96%-

As of 31 Mar 24, Anebulo Pharmaceuticals is held by 3.29% institutional shareholders, representing a 0.41% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 246-14.29%
31 Dec, 23740.00%
30 Sep, 23525.00%
30 Jun, 23433.33%
31 Mar, 233-25.00%
31 Dec, 224-
30 Sep, 22433.33%
30 Jun, 223-
31 Mar, 223-
31 Dec, 213200.00%
30 Sep, 211-87.50%
30 Jun, 218-

6 institutional shareholders have increased their position in ANEB stock as of 31 Mar 24 compared to 7 in the previous quarter (a -14.29% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 242-33.33%
31 Dec, 23350.00%
30 Sep, 232-
30 Jun, 232100.00%
31 Mar, 231-66.67%
31 Dec, 223-40.00%
30 Sep, 225400.00%
30 Jun, 221-66.67%
31 Mar, 22350.00%
31 Dec, 212-50.00%
30 Sep, 214-
30 Jun, 21--

2 institutional shareholders have reduced their position in ANEB stock as of 31 Mar 24 compared to 3 in the previous quarter (a -33.33% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 248-38.46%847,805-88.35%3.29%0.41%6-14.29%2-33.33%
31 Dec, 231318.18%7,278,9933.24%28.22%3.57%740.00%350.00%
30 Sep, 2311-7,050,4910.26%28.12%3.74%525.00%2-
30 Jun, 231122.22%7,031,8832.86%27.43%3.86%433.33%2100.00%
31 Mar, 239-25.00%6,836,130-2.98%26.67%3.53%3-25.00%1-66.67%
31 Dec, 221220.00%7,046,3072.97%27.49%3.22%4-3-40.00%
30 Sep, 221025.00%6,842,91246.28%29.22%7.28%433.33%5400.00%
30 Jun, 228-4,677,84711.63%20.04%6.22%3-1-66.67%
31 Mar, 228-4,190,412-0.07%17.95%5.56%3-350.00%
31 Dec, 21814.29%4,193,3070.24%17.96%5.59%3200.00%2-50.00%
30 Sep, 217-12.50%4,183,214-0.40%17.92%3.40%1-87.50%4-
30 Jun, 218-4,199,876-22.96%-8---

Anebulo Pharmaceuticals Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 20, 2023English Aron R.director, 10 percent owner G-GiftSell300,000---

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 08, 2024Cundy Kenneth Cofficer Chief Scientific OfficerA-AwardBuy72,613$2.72$197.51K72,613
Mar 01, 2024Cundy Kenneth Cofficer Chief Scientific OfficerA-AwardBuy72,613$2.78$201.86K72,613
Dec 20, 2023English Aron R.director, 10 percent owner G-GiftBuy300,000--5,366,290
Dec 20, 2023English Aron R.director, 10 percent owner A-AwardBuy300,000--300,000
Dec 20, 2023English Aron R.director, 10 percent owner G-GiftSell300,000---
Oct 11, 2023Cunningham, Richard Anthonydirector, officer Chief Executive OfficerA-AwardBuy600,000$3.03$1.82M600,000
Oct 11, 2023Cunningham, Richard Anthonydirector, officer Chief Executive OfficerBuy----
Oct 10, 2023SHAH BIMAL R.director-A-AwardBuy26,097$3.03$79.00K26,097
Oct 10, 2023SHAH BIMAL R.director Buy----
Oct 02, 2023George Danofficer-Buy----
Apr 04, 2023GARDINER SANDRA A.officer-Buy----
Dec 13, 2022Cundy Kenneth Cofficer Chief Scientific OfficerA-AwardBuy35,017--35,017
Dec 13, 2022ALLEN SIMONofficer Chief Executive OfficerA-AwardBuy70,246--70,246
Nov 02, 2022Calloway Nathanieldirector-A-AwardBuy59,149--59,149
Nov 02, 2022Calloway Nathaniel--Buy----
Nov 02, 2022Calloway Nathanieldirector Buy----
Oct 04, 2022Lawler Joseph F.director-A-AwardBuy30,425--30,425
Oct 04, 2022Lin Kennethdirector-A-AwardBuy30,425--30,425
Oct 03, 2022Parschauer Karah Herdmandirector-A-AwardBuy30,425--30,425
Oct 03, 2022Aryeh Jasondirector-A-AwardBuy30,425--30,425

The last insider sell of Anebulo Pharmaceuticals's stock was made by English Aron R. on Dec 20 2023, selling 300,000 shares at - per share (valued at -).

Anebulo Pharmaceuticals Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20241--
Q4 202341400.00%
Q3 2023---
Q1 2023---
Q4 20223--
Q2 20228--
Q1 20221--
Q4 20214--
Q2 20212825.00%

1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Anebulo Pharmaceuticals's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q4 2023---
Q3 2023---
Q1 2023---
Q4 2022---
Q2 2022---
Q1 2022---
Q4 20214--
Q2 2021---

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Anebulo Pharmaceuticals's stocks.

Anebulo Pharmaceuticals Peer Ownership


TickerCompany
ANTXAN2 Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
ANABAnaptysBio, Inc.
PMVPPMV Pharmaceuticals, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
ADAGAdagene Inc.
MOLNMolecular Partners AG
OPTOpthea Limited

ANEB Ownership FAQ


Anebulo Pharmaceuticals is owned by institutional shareholders (3.29%), insiders (65.38%), and public (31.33%). The largest institutional shareholder of Anebulo Pharmaceuticals is 22NW, LP (20.81% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).

Anebulo Pharmaceuticals's major institutional shareholders are 22NW, LP, LVW ADVISORS, LLC, NANTAHALA CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, and IKARIAN CAPITAL, LLC. The top five shareholders own together 27.44% of the company's share outstanding.

As of Mar 2024, there are 8 institutional shareholders of Anebulo Pharmaceuticals.

22NW, LP owns 5.37M shares of Anebulo Pharmaceuticals, representing 20.81% of the company's total shares outstanding, valued at $15.4M (as of Mar 2024).

As of Mar 2024, LVW ADVISORS, LLC holds 642.04K shares of Anebulo Pharmaceuticals (ANEB), compromising 2.49% of the company, valued at $1.84M.

NANTAHALA CAPITAL MANAGEMENT, LLC is the third largest holder of Anebulo Pharmaceuticals. The company owns 511.07K of the company's shares outstanding (worth $1.47M).